Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average of $5.44

Capricor Therapeutics Inc (NASDAQ:CAPR) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $5.44 and traded as high as $6.03. Capricor Therapeutics shares last traded at $5.93, with a volume of 276,550 shares traded.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CAPR. Cantor Fitzgerald assumed coverage on Capricor Therapeutics in a report on Friday, January 5th. They issued an “overweight” rating and a $8.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research report on Friday, March 1st. Finally, StockNews.com raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th.

Capricor Therapeutics Trading Down 9.0 %

The company has a market cap of $159.08 million, a P/E ratio of -5.80 and a beta of 3.99. The company’s 50-day moving average price is $5.50 and its two-hundred day moving average price is $4.28.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.21. The business had revenue of $12.09 million during the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. As a group, analysts anticipate that Capricor Therapeutics Inc will post -0.83 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently made changes to their positions in CAPR. Citigroup Inc. acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $211,000. Renaissance Technologies LLC raised its position in shares of Capricor Therapeutics by 32.6% during the 1st quarter. Renaissance Technologies LLC now owns 30,521 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 7,500 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of Capricor Therapeutics during the 1st quarter valued at approximately $126,000. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at approximately $109,000. Finally, UBS Group AG raised its position in shares of Capricor Therapeutics by 326.0% during the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 22,462 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.